Wednesday, June 18, 2025 6/18/2025

HIV-1 PROTEASE CD4+ T CELL EPITOPES AND DRUG-INDUCED MUTATIONS

Award Number: R03AI066961
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2007
PERIOD OF PERFORMANCE END DATE: 03/31/2010

Group Awards By:

View Award Description

HIV-1 PROTEASE CD4+ T CELL EPITOPES AND DRUG-INDUCED MUTATIONS - DESCRIPTION (provided by applicant): This R03 application aims at providing data in support of the underlying hypothesis that CD4+ T cell responses towards HIV-1 protease neoepitopes created by drug escape mutations can help to control the growth of resistant variants. A significant proportion of Pi-treated HIV-1 infected (HIV-1+) patients develop resistance mutations, and CD8+ T cell responses against such drug-induced mutant epitopes have been documented. It has been suggested that such a T cell response against epitopes under drug pressure may keep mutants under immunological control, or delay the emergence of drug resistance mutations, in patients undergoing antiretroviral (ARV) treatment. Given the importance of CD4+ T cell responses in maintaining CD8+ T cell memory, we will investigate, for the first time, the recognition of sites of Pi-induced mutations by CD4+ T cells of Pi-treated HIV-1 + patients. The study will have a cross-sectional (Aim 1) and a longitudinal arm (Aim 2). To search for CD4+ T cell responses against mutant protease epitopes (Aim 1), we will synthesize peptides representing wild-type and neoepitope sequences, incorporating major Pi-induced mutation sites and predicted to bind to multiple HLA-DR molecules in silico. To evaluate their promiscuity, we will assess their ability to bind multiple HLA-DR molecules in vitro. Subsequently, we will test the T cell responses from Pi-treated HIV-1 + patients to such peptides by IFN-gamma ELISPOT, CFSE proliferation and flow cytometry. Sequences of recognized peptides will be compared to endogenous HIV-1 protease sequence. In the longitudinal arm (Aim 2), we will study patients whose HIV-1 isolates developed new mutations in the protease gene along the 1-year observation period. Among such patients, we will compare disease evolution between the groups that developed or failed to develop CD4+ T cell responses to neoepitopes. We expect to obtain information as to whether the convergence of drug and immune pressure influences mutations leading to immune escape or drug resistance. The information to be obtained may help develop immune strategies that could be applied to enhance the immune response against mutant HIV-1 and fight the emergence of Pi-resistant HIV-1 strains.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2009 ( Subtotal = $52,974 )
2009	2009	UNIVERSITY OF SAO PAULO	CAIXA POSTAL 11.273-9	SAO PAULO				BRA	Allergy and Infectious Diseases Research	000	3	3/18/2009	NON-COMPETING CONTINUATION	$47,677
2009	2009	UNIVERSITY OF SAO PAULO	CAIXA POSTAL 11.273-9	SAO PAULO				BRA	Allergy and Infectious Diseases Research	001	3	6/9/2009	NON-COMPETING CONTINUATION	$5,297
														Subtotal = $52,974

Issue Date FY: 2008 ( Subtotal = $52,974 )
2008	2008	UNIVERSIDADE DE SAO PAULO	AVE LINEU PRESTES 1374	SAO PAULO				BRA	Allergy and Infectious Diseases Research	000	2	4/21/2008	NON-COMPETING CONTINUATION	$52,974
														Subtotal = $52,974

Issue Date FY: 2007 ( Subtotal = $54,000 )
2007	2007	UNIVERSIDADE DE SAO PAULO	AVE LINEU PRESTES 1374	SAO PAULO				BRA	Allergy and Infectious Diseases Research	000	1	3/13/2007	NEW	$54,000
														Subtotal = $54,000

Grand Total All Awards = $159,948

Top

All Categories

About

Search

Reports

Data Submission

Award Information

HIV-1 PROTEASE CD4+ T CELL EPITOPES AND DRUG-INDUCED MUTATIONS

Award Number: R03AI066961

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2007

PERIOD OF PERFORMANCE END DATE: 03/31/2010

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer